Enterprise Value
-479.6M
Cash
1.847B
Avg Qtr Burn
-90.5M
Short % of Float
5.70%
Insider Ownership
14.26%
Institutional Own.
75.95%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Sotrovimab VIR-7831 (GSK4182136) Details COVID-19, Infectious disease | Phase 3 Update | |
VIR-3434 +/- VIR-2218 +/- PEG-IFNα Details Infectious disease, Hepatitis B | Phase 2 Data readout | |
Phase 2 Data readout | ||
VIR-3434 + VIR-2218 Details Infectious disease, Hepatitis Delta Virus Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2 Data readout | |
VIR-2482 (Universal prophylaxis) Details Influenza, Infectious disease | Phase 2 Update | |
VIR-1388 (HVTN 142) Details Infectious disease, Human immunodeficiency virus, Vaccine | Phase 1 Data readout | |
VIR-1111 Details Infectious disease, Human immunodeficiency virus, Vaccine | Phase 1 Update | |
Sotrovimab VIR-7831 (GSK4182136) Details COVID-19, Infectious disease | Failed Discontinued |